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Acute myeloid leukemia (AML) is the most common acute leukemia in American adults and portends a poor prognosis if
untreated. Commonly, AML presents with symptoms related to concurrent leukopenia, anemia, or thrombocytopenia; however,
due to its ability to affect many organ systems in the body, AML can have a highly varied clinical presentation. One such
presentation is myocarditis, which is a rarely reported manifestation of AML. Myocarditis can have a varied clinical picture and
often requires exclusion of other causes of cardiac dysfunction. Sweet syndrome, also known as acute febrile neutrophilic
dermatosis, is another presentation of AML; however, it is more commonly associated with AML than cardiac involvement. Sweet
syndrome can occur in patients with an already established malignancy or can occur de novo in a patient with previously
undiagnosed cancer and, interestingly, can also be accompanied by extracutaneous manifestations, one of which is myocarditis.
Herein, we report a case of a 45-year-oldmale with a history of obesity and depression who presented with chest pain, a tender and
diffuse rash, and pancytopenia. Heart catheterization performed at outside institution was negative for coronary artery disease.
CardiacMRI images were compatible withmyocarditis. Dermal biopsy of the rash was consistent with sweet syndrome. Peripheral
blood flow cytometry and bone marrow biopsy confirmed the diagnosis of AML. He was treated with an induction chemotherapy
regimen of 7 days of cytarabine and 3 days of daunorubicin with resolution of his chest pain and skin lesions. )e patient had
persistent leukemia cells on day 14 postinduction bone marrow biopsy and was treated with high-dose cytarabine reinduction
treatment. Bone marrow biopsy with count recovery after reinduction therapy revealed complete response (CR).
1. Introduction
Acute myeloid leukemia (AML) is the most common acute
leukemia in American adults, accounting for 80% of all
leukemia and totaling to a yearly incidence of 20,000 cases in
the US [1]. AML is known to have a highly varied clinical
presentation due to its ability to infiltrate and affect many
organ systems in the body. One such association is a clinical
entity known as sweet syndrome, which is also known as
acute febrile neutrophilic dermatosis. Sweet syndrome is
characterized by discrete, tender skin lesions with a heavy
infiltrate of mature neutrophils and may be accompanied by
extracutaneous disease. In up to 20% of cases, sweet syn-
drome is associated with malignancy with AML being the
most frequent [2]. It can occur in patients with established
diagnosis of malignancy as a paraneoplastic disorder, or it
could occur prior to a formal diagnosis of malignancy.
Furthermore, one potential extracutaneous manifestation of
sweet syndrome is myocarditis, which is also a rare pre-
sentation of AML. Autopsies of patients who expired due to
AML have shown that up to 37.1% have cardiac leukemic
infiltrates [3]. However, myocarditis is a very uncommon
manifestation of this, with our literature review producing
only three case reports describing this association with AML.
Our literature review also produced only four cases of pa-
tients with concurrent sweet syndrome and myocarditis.
Here, we present a patient who presented with chest pain
and increased cardiac enzymes secondary to myocarditis, a
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rash that was biopsy proven to be sweet syndrome, and
pancytopenia secondary to new diagnosis of AML.
2. Case Presentation
A 45-year-old male with a past medical history of hyper-
tension and depression presented to an outside hospital’s
emergency department with a primary complaint of chest
pain of one day duration. He was in his usual state of health
prior to the onset of the chest pain. )is chest pain was
progressively worsening, substernal, radiated to his back,
and was unaffected by position. On presentation, he was
found to have elevated troponins and was provided nitro-
glycerin, which relieved his chest pain. Initial electrocar-
diogram (ECG) was without any ST elevations. He was
subsequently taken for left heart catheterization and found
to have nonobstructive coronary artery disease. He was
discharged to home on metoprolol, aspirin, statin, and a
proton pump inhibitor. He was also discharged on indo-
methacin due to suspicion of myocarditis at that time. After
discharge, however, his chest pain continued to worsen.
Around that time, he also started to notice a painful dark
rash on his legs.
)e worsening chest pain and new onset rash prompted
him to return to the ED about five days after his recent
discharge, and he was subsequently transferred to our
hospital’s ED. On presentation, he further endorsed strong
feelings of fatigue over the prior few days and was admitted
to several nights of drenching sweats. He also had subjective
fevers and chills. He denied any recent shortness of breath,
documented fevers, changes in weight, or sensation of heart
palpitations. )e patient was afebrile with a heart rate of 76,
blood pressure of 129/63, a respiratory rate of 18, and 99%
oxygen saturation in room air. On physical exam, the patient
was an obese male in no acute distress. He was observed to
have a linear grouping of well-circumscribed tender papules
with a deep red to purple base on his left thigh with the
largest lesion being about six centimeters. He also had
similar smaller lesions located on his right forearm, left
upper arm, and left cheek. Cardiopulmonary exam was
normal with clear lungs in all fields and no abnormal heart
sounds or peripheral edema. )e rest of systemic exami-
nation was normal.
Initial laboratory evaluation revealed elevated high-
sensitivity troponins at 958 ng/L (<19 ng/L) and elevated
NT-proBNP at 1104 pg/mL (<449 pg/mL). Repeat high-
sensitivity troponin level 2 hours later was stable at 899 ng/L.
His initial ECG showed no acute changes (Figure 1), and a
bedside echocardiogram showed a preserved ejection
fraction.
Continued workup revealed a white blood cell count of
2.20 k/µL (3.7–10.3 k/uL), an absolute neutrophil population
of 0.75 k/µL, 21% peripheral blasts, hemoglobin of 8.7 g/dL
(13.7–17.5 g/dL), and a platelet count of 116 k/µL (155–369 k/
uL). )is pancytopenia with peripheral blasts and an elevated
LDH of 335U/L (116–250U/L) raised strong suspicion for
acute leukemia. His uric acid, creatinine, and liver function
tests were all within normal limits. Peripheral blood smear
confirmed pancytopenia with circulating blasts. Peripheral
blood flow cytometry was significant for expanded myeloid
blast population with 19% of the cells. Subsequent bone
marrow biopsy confirmed acute myeloid leukemia with 62%
blasts by flow cytometry in a hypercellular marrow with
markedly decreased background hematopoiesis. Immuno-
phenotype showed blasts expressing CD34, CD117, partial
CD13, dim CD33, HLA-DR, CD7, CD38, and moderate to
dim CD45. Bone marrow aspirate smear is shown in Figure 2.
Molecular testing for NPM1 and FLT3 was negative. FISH
panel was positive for t(11q23) and gain of 3′KMT2A, di-
agnosing him with poor-risk mixed leukemia lineage- (MLL-)
associated AML.
A dedicated cardiac MRI (Figure 3) demonstrated evi-
dence of nonischaemic myocardial inflammation consistent
with myocarditis. It also demonstrated multiple areas of late
subepicardial gadolinium enhancement in the lateral wall
and midmyocardial enhancement in the septum. Of note,
the MRI showed a normal ejection fraction and no asso-
ciated pericardial effusion. CMV PCR, coxsackie viral PCR,
adenovirus PCR, Lyme serology, anaplasmosis serology,
ehrlichiosis serology, mycoplasma PCR, influenza A and B
testing, COVID-19 PCR, HIV screen, and hepatitis testing
were negative. Furthermore, syphilis RPR, ANA, ANCA,
and blood and urine cultures were also negative. With these
negative tests, a presumptive diagnosis of AML-related
myocarditis was made via exclusion. A biopsy of the pa-
tient’s skin lesions was then performed, revealing for a
“dense dermal infiltrate of polymorphonuclear cells in a
pattern that would fit best with a neutrophilic dermatosis,”
qualifying a final diagnosis of sweet syndrome. )e histo-
logic image of the skin biopsy at both low and high mag-
nification is shown in Figure 4.
)e patient was started on “7 + 3” induction chemo-
therapy with seven days of cytarabine dosed at 100mg/m2
daily and three days of daunorubicin dosed at 60mg/m2
daily. )e patient had complete resolution of his chest pain
shortly thereafter and marked improvement in his skin
lesions. His day 14 postinduction bone marrow biopsy
showed 60% cellularity with 50% blasts consistent with prior
leukemic blasts by flow cytometry. Due to persistent pres-
ence of leukemia, he was started on high-dose cytarabine
(HiDAC) reinduction chemotherapy. After HIDAC, the
patient had count recovery, and bone marrow biopsy at that
time revealed no evidence of acute myeloid leukemia;
therefore, he was determined to have complete response. He
was discharged from the hospital seven weeks after his
admission date. At the time of discharge, his skin lesions had
healed to a significant extent.
3. Discussion
Acute myeloid leukemia has a highly variable clinical pre-
sentation with rare associations documented. AML-related
myocarditis is one such poorly studied disease entity. In
general, myocarditis is a disease secondary to inflammation
of the cardiac muscle and has a nonspecific clinical pre-
sentation that ranges from acute chest pain to new onset
heart failure to cardiogenic shock, among others. Diagnosis
of clinically suspectedmyocarditis is based on a combination
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Figure 1: EKG performed in the ED showed a heart rate of 74 and a regular sinus rhythm, with no acute disease processes.
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of the clinical presentation and diagnostic findings, which
can include characteristic tissue imaging on cardiac MRI [5].
)is diagnosis via cardiac MRI is established via the updated
Lake Louise criteria where both of the following criteria
must be met: demonstration of edema, with regional or
global myocardial signal intensity increase in T2-weighted
images or with prolonged T2 relaxation times on native T2
mapping, as well as late gadolinium enhancement in a
nonischaemic distribution on inversion recovery-prepared
gadolinium-enhanced T1-weighted images [4]. Often, cor-
onary arterial disease has to be ruled out via angiography. Of
course, gold standard diagnosis of myocarditis is based on
endomyocardial biopsy [6]. Infiltration of the heart muscle
by malignant leukemia cells is a known sequela of AML, but
this process is usually subclinical for unknown reasons [3].
Of 420 autopsies of myelogenous or lymphocytic leukemia
patients evaluated by Roberts et al., 288 (69%) of patients
had some degree of leukemic involvement of the heart. 190
of these patients had pericardial involvement, which was the
most common cardiac site of involvement [3]. AML with an
initial presentation of pericarditis is estimated to occur in 1-
2% of cases. Myocarditis, however, is less frequently
documented. In our literature review, we identified only
three previous case reports documenting AML-related
myocarditis, which are described in Table 1 [7–9]. Of note,
pericarditis was also present in two of the three cases.
Furthermore, two of the three patients had cardiac MRI with
characteristic findings, and all three patients had negative
coronary artery angiography.
In contrast, acute myeloid leukemia is associated with
dermatologic involvement more commonly, with presence
in about 10% of new cases. )ese skin lesions include er-
ythematous nodules, papules, or plaques, among others
[10, 11]. One of these dermatologic associations is an entity
known as sweet syndrome. )e classical form of sweet
syndrome, also known as neutrophilic dermatosis, is a rare
disorder consisting of fever, neutrophilia, and tender ery-
thematous skin lesions characterized by mature neutrophils
(c) (d)
Figure 3: Cardiac MRI showed features consistent with myocarditis satisfying the updated Lake Louise criteria [4], visualized in these
images. (a) Mid-short-axis native T1 mapping demonstrated elevated native myocardial T1 at 1173ms (local lab normal reference:
950–1050ms). (b) Mid-short-axis T2 mapping demonstrated elevated myocardial T2 at 58ms (normal reference: 40–50ms). (c) Mid-short-
axis phase-sensitive inversion recovery late gadolinium enhancement image showed multiple areas of subepicardial enhancement in the
lateral wall, as well as midmyocardial enhancement in the septum. (d) Four-chamber late gadolinium enhancement image demonstrated
midmyocardial enhancement in the septum and subepicardial to midmyocardial enhancement in the lateral wall.
(a) (b)
Figure 4: Skin biopsy showed dense dermal infiltrate of polymorphonuclear cells at both low (a) and high (b) magnification.
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in the upper dermis [12]. Numerous precipitating factors
have been identified, including inflammatory bowel disease,
pregnancy, and administration of drugs such as G-CSF,
among others. Sweet syndrome cases are very often asso-
ciated with malignancy, with AML being the most common
offender. Malignancy-associated sweet syndrome has been
documented on numerous occasions to be the presenting
symptom of previously undiagnosed neoplastic process;
however, it can also occur as a paraneoplastic process in a
patient with an already established diagnosis of malignancy.
)e exact pathogenesis of sweet syndrome is not fully un-
derstood; various proposed mechanisms have included an
exaggerated hypersensitivity reaction, heritable mutations
predisposing to the illness, and dysregulated cytokine (es-
pecially G-CSF) production. )e lesions classically appear in
multiple locations on the body, with one study suggesting
that the upper and lower extremities and trunk were most
commonly affected [13]. )is study also found that a ma-
jority of the lesions were erythematous, with plaques being
the most common morphology, but with vesicles or pustules
being a known variant of the disease, appearing just under
20% of the time. )e lesions were tender to palpation in 43%
of cases and pruritic in 18% of cases. )e gold standard for
diagnosis is a biopsy showing the characteristic diffuse in-
filtration by mature neutrophils. First-line treatment is
systemic corticosteroids, which typically cause immediate
improvement in symptoms, with subsequent resolution of
skin lesions [13]. Treatment of the underlying cause, if
identified, is also indicated.
Our patient’s presentation was consistent with malig-
nancy-associated sweet syndrome in several ways. )e
papular lesions were tender, erythematous, and character-
istically distributed on his lower and upper extremities. His
previously undiagnosed AML is the most common malig-
nancy associated with sweet syndrome. A skin biopsy ul-
timately confirmed the disease, and his rash improved with
treatment of his malignancy. )is patient’s concurrent
myocarditis diagnosis was established with cardiac MRI
using the updated Lake Louise criteria [4]. His myocarditis
was likely related to his diagnosis of sweet syndrome due to
exclusion of other etiologies and occurring in the setting of
both sweet syndrome rash and acute leukemia, two known
Table 1: Myocarditis/myopericarditis in AML patients.
Age/sex Presentation Cardiac evaluation Leukemic evaluation Treatment Author
37/F
Acute exertional chest pain
with radiation to arms.
Negative coronary artery
angiography. TTE: EF of
50–55% with hypokinetic
right ventricle. Cardiac
MRI: EF of 33% with signal
changes consistent with
myocarditis.






ECG with ST elevations in
leads I, aVL, V1, and V2
and PR elevation in lead
AVR. Troponin elevated at
1.6 ng/mL. AML treatment not stated.
CBC showed WBC of
13.7 k/µL with 28% blasts,







ejection fraction of 40–45%.
)ere was mild hypokinesis
in the midinferior and mid-
anterolateral walls and no
pericardial effusions. TTE






AML. FISH analysis was







ECG with ST segment
elevation in leads I, II, aVL,
and V5 with PR elevation
and ST depression in aVR.
Troponin-I was 14.8 ng/
mL. CBC revealed
hemoglobin of 10.8 g/dL,
white cell count of 13,000/
µL, 56% blasts, absolute
neutrophil count of 1,430/
µL, and platelet count of
83×103/µL.
AML: 7 d cytarabine and




Acute chest pain. ECG
with ST elevation in





normal coronary arteries. Bone marrow biopsy: 47%




et al. [9]Cardiac MRI: cardiacdysfunction with areas of




AML: acute myeloid leukemia; CBC: complete blood count; ECG: electrocardiogram; EF: ejection fraction; FISH: fluorescence in situ hybridization; Hgb:
hemoglobin; HIDAC: high-dose cytarabine; Plts: platelets; TTE: transthoracic echocardiogram; WBC: white blood cells.
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CXR: chest X-ray; CRP: C-reactive protein; ECG: electrocardiogram; LA: left atrium; LV: left ventricle.
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associations. )e treating physicians still decided to treat
with an anthracycline-based induction chemotherapy regi-
men despite the finding of myocarditis. )is was because the
patient still had preserved heart function, was hemody-
namically stable, and was of young age with few comor-
bidities and thus would most benefit from high-intensity
induction chemotherapy. Fortunately, his chest pain never
recurred after treatment of his leukemia. Cases in the lit-
erature regarding the combination of sweet syndrome and
myocarditis are described in Table 2 [14–17]. All four pa-
tients were treated for their sweet syndrome with some form
of steroid administration. )ree of the four had complete
recovery from their disease; however, the fourth died due to
cardiac arrest shortly after presentation. Of significance,
there are no reported cases of sweet syndrome with con-
current myocarditis as symptoms of acute myeloid leukemia.
In conclusion, this patient had biopsy-proven neutro-
philic dermatosis and subacute myocarditis as presenting
symptoms of acute myeloid leukemia, supporting a diag-
nosis of sweet syndrome. Providers should be aware of this
clinical syndrome, especially because it may be the first
manifestation of underlying hematologic malignancy.
Data Availability
)e literature review data used to support the findings of this
study are included within the article.
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and J. Morais, “Comprometimento cardı́aco na śındrome de
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